CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced it signed a Commercial Supply Agreement with Baxter Healthcare Corporation. This agreement provides additional manufacturing capacity for Javelin’s injectable diclofenac, DylojectTM,supplementing its existing supply and manufacturing agreement. Under the Agreement, Baxter will serve as a secondary manufacturer of Dyloject pending regulatory approval. The Agreement has a three-year, renewable term and sets forth minimum purchase and production requirements.
